| Arthritis, Psoriatic
Stelara vs Rayos
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Stelara vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Stelara based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Stelara, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stelara
Rayos
At A Glance
SC injection
Every 8-12 weeks
IL-12/23 antagonist
Oral
Daily
Corticosteroid
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.
Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.
Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression
Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia
Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stelara
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Stelara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Stelara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Stelara withMe Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
StelaraView full Stelara profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.